Binnopharm Group Ranks Fourth Among Pharmaceutical Manufacturers in the Russian Retail Market in September
07.11.2024
According to the results of September, the leading pharmaceutical company Binnopharm Group occupies the fourth position in the Russian retail market (sell out, data from the AlphaRM analytical agency). In the first nine months of 2024, the company rose two places in the manufacturer rankings and took sixth place among all corporations, demonstrating growth of 22% year to year.
At the same time, Binnopharm Group continues to confirm its position in the OTC drugs market and ranks third in sales in the pharmacy segment (sell out) in value terms with an increase of 20% year to year.
In the overall market ranking (retail and tender), the company ranks 11th in rubles with a 19% increase year to year.
The growth of the entire Russian pharmaceutical market in commercial retail in January–September 2024 in value terms amounted to 17%. Thus, Binnopharm Group grew above the market by 5 percentage points (22% vs. 17%).
Ekaterina Slavgorodskaya, Director of Sales and Promotion, Binnopharm Group: «Despite all the volatility of the market situation, we remain a steadily growing company. Having outlined a multi-level development strategy for itself, Binnopharm Group is persistently moving towards achieving its goals. The high key rate, personnel shortage, unstable demand, and tough competition among manufacturers did not become obstacles to strengthening the company’s position in the market.
We are expanding our portfolio of drug products, believe in partnership with distributors and pharmacy chains, and are strengthening our promotional activities and work with doctors and pharmacists in Russia and abroad. The use of digital technologies and omnichannel promotion allows us to move forward without stopping for a second».
At the same time, Binnopharm Group continues to confirm its position in the OTC drugs market and ranks third in sales in the pharmacy segment (sell out) in value terms with an increase of 20% year to year.
In the overall market ranking (retail and tender), the company ranks 11th in rubles with a 19% increase year to year.
The growth of the entire Russian pharmaceutical market in commercial retail in January–September 2024 in value terms amounted to 17%. Thus, Binnopharm Group grew above the market by 5 percentage points (22% vs. 17%).
Ekaterina Slavgorodskaya, Director of Sales and Promotion, Binnopharm Group: «Despite all the volatility of the market situation, we remain a steadily growing company. Having outlined a multi-level development strategy for itself, Binnopharm Group is persistently moving towards achieving its goals. The high key rate, personnel shortage, unstable demand, and tough competition among manufacturers did not become obstacles to strengthening the company’s position in the market.
We are expanding our portfolio of drug products, believe in partnership with distributors and pharmacy chains, and are strengthening our promotional activities and work with doctors and pharmacists in Russia and abroad. The use of digital technologies and omnichannel promotion allows us to move forward without stopping for a second».
